Cargando…
S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis
SARS-CoV-2 recognizes, via its spike receptor-binding domain (S-RBD), human angiotensin-converting enzyme 2 (ACE2) to initiate infection. Ecto-domain protein of ACE2 can therefore function as a decoy. Here we show that mutations of S19W, T27W, and N330Y in ACE2 could individually enhance SARS-CoV-2...
Autores principales: | Ye, Fei, Lin, Xi, Chen, Zimin, Yang, Fanli, Lin, Sheng, Yang, Jing, Chen, Hua, Sun, Honglu, Wang, Lingling, Wen, Ao, Zhang, Xindan, Dai, Yushan, Cao, Yu, Yang, Jingyun, Shen, Guobo, Yang, Li, Li, Jiong, Wang, Zhenling, Wang, Wei, Wei, Xiawei, Lu, Guangwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444507/ https://www.ncbi.nlm.nih.gov/pubmed/34531369 http://dx.doi.org/10.1038/s41392-021-00756-4 |
Ejemplares similares
-
Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020) -
Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding
por: Lin, Sheng, et al.
Publicado: (2022) -
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus
por: He, Cai, et al.
Publicado: (2021) -
Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants
por: Lei, Hong, et al.
Publicado: (2022) -
A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding
por: Yang, Jing, et al.
Publicado: (2022)